Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nachbagauer

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2022
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in miceCarly M Bliss, Alec W Freyn, Tom G Caniels, et al.
Science (New York, N.Y.)|April 1, 2017
Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunitySusana V Bardina, Paul Bunduc, Shashank Tripathi, et al.
Ebiomedicine|May 28, 2024
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoproteinCarly M Bliss, Raffael Nachbagauer, Chiara Mariottini, et al.
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
NPJ Vaccines|December 17, 2019
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohortsRaffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2020
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceAlec W Freyn, Jamile Ramos da Silva, Victoria C Rosado, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2021
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopesAlec W Freyn, Julianna Han, Jenna J Guthmiller, et al.
Cell Reports|December 19, 2019
Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A VirusesRaquel Muñoz-Moreno, Carles Martínez-Romero, Daniel Blanco-Melo, et al.
The Lancet. Infectious Diseases|April 24, 2022
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trialNicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, et al.
Human Vaccines & Immunotherapeutics|April 2, 2025
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titersBoris Kandinov, Mieke Soens, Wenmei Huang, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2022
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in miceCarly M Bliss, Alec W Freyn, Tom G Caniels, et al.
Science (New York, N.Y.)|April 1, 2017
Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunitySusana V Bardina, Paul Bunduc, Shashank Tripathi, et al.
Ebiomedicine|May 28, 2024
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoproteinCarly M Bliss, Raffael Nachbagauer, Chiara Mariottini, et al.
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
NPJ Vaccines|December 17, 2019
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohortsRaffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2020
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceAlec W Freyn, Jamile Ramos da Silva, Victoria C Rosado, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2021
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopesAlec W Freyn, Julianna Han, Jenna J Guthmiller, et al.
Cell Reports|December 19, 2019
Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A VirusesRaquel Muñoz-Moreno, Carles Martínez-Romero, Daniel Blanco-Melo, et al.
The Lancet. Infectious Diseases|April 24, 2022
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trialNicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, et al.
Human Vaccines & Immunotherapeutics|April 2, 2025
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titersBoris Kandinov, Mieke Soens, Wenmei Huang, et al.
Pageof 11